Clinical trial NCT03081338: A Programme for Amyotrophic Lateral Sclerosis Care in Europe
Official title: A Programme for Amyotrophic Lateral Sclerosis Care in Europe
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ALS (Amyotrophic Lateral Sclerosis)
MND (Motor Neurone DIsease)
Keywords: ALS, MND, Care, Patient journey
Lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Sponsor class: OTHER
First posted: 2017-03-16
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A mix of incident and prevalent cases will be included in order to capture patients at different stages of the disease trajectory. The total study population will contain 600 patients (300 newly diagnosed and 300 prevalent).

Brief summary: Amyotrophic Lateral Sclerosis (ALS) or else known as Motor Neurone Disease (MND) is a rapidly progressive fatal neurological disease that strikes in the prime of life, and for which there is no treatment. The principal aim of management is to maintain quality of life and reduce the symptoms of the disease. This requires a multidisciplinary approach using best practice for symptom alleviation, including innovation approaches towards maximising quality of life. The purpose of this study is to use existing information drawn from partner countries into a system of care that is available to people with amyotrophic lateral sclerosis at the correct time, in the correct format and in a cost effective manner. This will be achieved by collecting details of patient and carer experiences across all stages of from diagnosis to end of life, including decision making in the terminal stages of the disease. A health economic analysis will help to identify the overall costs of disease management, provide models of increased efficiency that preserve and maximize quality of life, and begin to develop novel health economic measurement tools for terminal neurological illness. The completed project will provide a user-friendly best practice programme for amyotrophic lateral sclerosis that can be modified for management of other related degenerative diseases of the nervous system.

Detailed description: This is a prospective multi-centre observational research project that will be carried out by 8 European partners in 9 sites: 1 in Ireland (Dublin), 1 in the Netherlands (Utrecht), 2 in the United Kingdom (UK) (Sheffield and London), 2 in Italy (Turin and Milan), 2 in Germany (Berlin and Munich), and 1 in Belgium (Leuven). In terms of data collection, the study consists of 3 substudies and will be organised in 6 interlinked work packages spanning clinical, epidemiological and health services research.

All partners will contribute in participant recruitment and collect comparable data, which will be used for fulfilling the deliverables of each work package. Central co-ordination of research activities in the 2 UK sites will be undertaken in Sheffield. This protocol concerns research activities in relation to the ALS-CarE project involving the 2 UK-based participating sites.

Following ethical and research governance approvals, ALS-CarE officially started on 1st April 2014 and will run for 3 years. Participant recruitment will commence following ethical and research governance approval and will occur for the first 4 months at the Sheffield and King's College MND Care Centres. The follow-up period of each participant will take 12 months depending on the rate of progression of the illness. Finally, a period of 11 months at the end of the project will enable analysis of data, dissemination of findings and report writing.

SCIENTIFIC SUMMARY

Background:

Amyotrophic Lateral Sclerosis (ALS) or else known as Motor Neurone Disease (MND) is a progressive neurodegenerative disease that strikes in the prime of life. There are currently no effective disease modifying therapies for ALS and death usually occurs within 3 years of symptom onset. Management is palliative and is aimed at maximising quality of life and minimising the burden of disease. The complexity and rapidly progressive nature of ALS requires a responsive multidisciplinary care system that that is built on reliable disease staging and evidence based symptom management.

Aim:

To incorporate detailed clinical information drawn from population based sources into a responsive care programme.

Plan of investigation:

A standardised staging system will be validated, and quality of life and patient experiences will be measured and management optimised across disease stages from diagnosis to end of life. Health economic analysis will identify key differences in resource utilisation and will be useful for pharmaco-economic analyses of new therapeutics.

Potential impact:

The completed project will provide a user-friendly best practice framework for ALS that can be modified for management of other neurodegenerative diseases.

Eligibility criteria: Inclusion Criteria:

* A diagnosis of definite, probable, laboratory supported or possible ALS according to the El Escorial criteria.

Exclusion Criteria:

* Patient cognitive impairment to the extent that they cannot complete an informed consent process

Primary outcomes:
measure: Calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions using the EuroQoL validated EQ-5D-5L questionnaire.
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Sheffield
country: United Kingdom
facility: Sheffield Institute for Translational Neuroscience
state: South Yorkshire
Study officials:
References: